Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TRELEGY ELLIPTA safely and effectively. See full prescribing information for TRELEGY ELLIPTA. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), for oral inhalation useInitial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
TRELEGY ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). TRELEGY ELLIPTA is indicated for the maintenance treatment of asthma in patients aged 18 years and older. TRELEGY ELLIPTA is NOT indicated for the relief of acute bronchospasm.
- generic_name
- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate
- product_names
- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate
- ndc
- 0173-0887, 0173-0887-10, 0173-0887-14, 0173-0887-61, 0173-0893, 0173-0893-10, 0173-0893-14, 0173-0893-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en